Search

A patent has been issued for a blood purification apparatus developed by Nikkiso Company Limited, which aims to estimate a patient's state of nutrition during blood purification treatment. The apparatus utilizes blood purification membranes to calculate colloid osmotic pressure, allowing for the assessment of parameters such as plasma total protein to determine the patient's nutritional status accurately. By detecting transmembrane pressure differences and utilizing a control unit, the apparatus can provide a method for estimating a patient's state of nutrition during blood purification treatment. [Extracted from the article]

A recent study from the Hong Kong University of Science and Technology has introduced a new method for in-vitro blood purification using tiny pinch holographic optical tweezers based on deep learning. This innovative system allows for accurate blood component detection and extraction, demonstrating high precision and efficiency in real-time blood fractionation. The research, supported by the Hong Kong Innovation and Technology Fund, opens new possibilities for blood treatment and has been peer-reviewed. For more information, readers can refer to the article "In-vitro Blood Purification Using Tiny Pinch Holographic Optical Tweezers Based On Deep Learning" in Biosensors and Bioelectronics. [Extracted from the article]

The patent application by Toray Industries Inc. focuses on a hollow fiber membrane for blood purification, specifically targeting the removal of extracellular vesicles from blood. The membrane's structure and characteristics aim to efficiently separate plasma components and pathogenic substances while maintaining biocompatibility. The inventors propose a specific design for the hollow fiber membrane to address the challenges associated with removing extracellular vesicles, emphasizing particle permeability and surface pore size. This innovation could potentially enhance blood purification processes and contribute to therapeutic advancements in hematology. [Extracted from the article]

A study conducted at the First Affiliated Hospital of Xinxiang Medical University in Henan, China, focused on the effects of integrated blood purification on haemodynamics and oxygen metabolism in children with severe sepsis. The research involved 12 children admitted to the pediatric intensive care unit, and the results showed improvements in various parameters after treatment. The study concluded that integrated blood purification can enhance haemodynamic and oxygen metabolism parameters in children with severe sepsis, suggesting its potential clinical value. [Extracted from the article]

A patent was issued to Nikkiso Company Limited for an attaching member designed for blood purification apparatuses. The invention aims to simplify the arrangement of flexible tubes within the apparatus, allowing for efficient use of limited space. The attaching member holds pump tubes for liquid delivery and includes features such as a transparent body and holding grooves for connectors. This innovation addresses the need for improved functionality in blood purification technology. [Extracted from the article]

Researchers from the University of Barcelona conducted a study on the use of extracorporeal blood purification (EBP) in reducing cardiac surgery-associated acute kidney injury (CSA-AKI) after cardiopulmonary bypass (CPB). The study involved 343 patients undergoing nonemergent cardiac surgery, with half receiving EBP and the other half receiving standard care. Results showed a significant reduction in CSA-AKI in the EBP group compared to the standard care group, particularly in patients with certain risk factors. The research was funded by the Public Health Ministry of Spain and Baxter International Inc., and the findings were published in JAMA. [Extracted from the article]

A patent was issued for a blood purification apparatus and a method of verifying medical components by the apparatus. The inventors aimed to improve the safety and efficiency of blood purification treatments by verifying the appropriateness of medical components before attachment to the apparatus body. The patent details a method involving reading component information from an information-holding unit on a sterile bag to ensure the components are suitable for treatment, ultimately enhancing the quality of care provided in medical institutions. [Extracted from the article]

A study published in Medical Devices & Surgical Technology Week discusses the use of nonselective extracorporeal blood purification in cardiac surgery patients, which was found to reduce the incidence of acute kidney injury post-surgery. The study focused on a nonemergent population of patients connected to a cardiopulmonary bypass circuit. For more information, readers can access the full study through the JAMA Network. [Extracted from the article]

A patent has been issued for a blood purification device by Nikkiso Company Limited in Tokyo, Japan. The device aims to facilitate priming work by adjusting the liquid level height in the gas-liquid separator during treatment and priming. It includes features such as liquid level adjustment units, sensors, and a gas-liquid separator to control the liquid level height effectively. The invention focuses on suppressing an increase in the amount of blood extracorporeally circulated during treatment while simplifying the priming process. [Extracted from the article]

Researchers have submitted a patent application for an "Oncodialysis System And Method For Personalized Autologous Cancer Vaccine And Blood Purification" to the USPTO. The system aims to prepare an autologous cancer vaccine for patients by filtering blood plasma to separate out tumor components and converting them into antigens using electromagnetic radiation. This method avoids the use of surgical invasive biopsies and aims to induce the patient's immune system to produce autologous antibodies against cancer. The patent application was filed by inventors David Michaeli and Menashe Michaeli from Ashkelon, Israel. [Extracted from the article]

Researchers from the National Taiwan University of Science and Technology have developed a method for preparing porous nanofiber/microparticles (PNfMp) membranes for endotoxin removal in blood purification. The membranes were created using electrospray technology and a binary solvent mixture system. The researchers also modified the surfaces of the membranes with polymyxin B (PMB) for enhanced endotoxin adsorption. The PMB-modified membranes demonstrated a high adsorption capacity for endotoxin and were able to remove endotoxin from human plasma with almost 100% efficiency. This research provides a promising strategy for improving blood purification methods. [Extracted from the article]

Nikkiso Company Limited, based in Tokyo, Japan, has been issued a patent for a blood purification apparatus. The patent describes a device that allows for different methods of blood purification, such as hemodialysis, hemofiltration, and hemodiafiltration, and different substitution methods, including pre-substitution, post-substitution, and pre- and post-substitution. The invention aims to improve the accuracy of measuring the amount of substitution fluid consumed and reduce the cost of heating bags used in the apparatus. The patent provides detailed descriptions and variations of the apparatus. [Extracted from the article]

Researchers at Shenyang University of Chemical Technology in China have developed a new method for selectively clearing circulating histones from the blood, which may have therapeutic implications for sepsis. Histones are pathogenic factors that contribute to sepsis, but effectively removing them from the bloodstream has been challenging due to their structural similarity to normal blood proteins and interference from other biomacromolecules. The researchers designed a dodecapeptide-based functional polymer that can selectively adsorb circulating histones while exhibiting negligible affinities for common blood proteins. This material demonstrated the ability to efficiently capture histones from both model solutions and whole blood samples, making it a promising approach for blood purification in sepsis treatment. [Extracted from the article]

A systematic review conducted by researchers at San Bortolo Hospital in Vicenza, Italy, examined the effects of different dialysis modalities on chronic kidney disease-associated pruritus (CKD-aP). The review included 8 randomized controlled trials, 3 observational studies, and 6 prospective clinical trials. The researchers found that, apart from hemadsorption, the current evidence for dialytic treatment of CKD-aP is weak. They concluded that more high-quality studies are needed to confirm the long-term benefits of blood purification therapies in treating CKD-aP. [Extracted from the article]

A patent application titled "Blood Purification Apparatus" has been published online by the US Patent and Trademark Office. The patent application, filed by inventor Yuki OBATA, describes a blood purification apparatus that aims to improve the disinfection process by providing a heating unit that can quickly heat a disinfection liquid. The apparatus includes a disinfector, a heating unit, and a controller that controls the blood purification treatment, disinfection process, and heating process. The invention aims to provide a blood purification apparatus that can easily perform heating and complete the disinfection process quickly. The assignee for this patent application is Nikkiso Co. Ltd. [Extracted from the article]

A patent has been issued for a blood purification device developed by Nikkiso Co. Ltd. The device aims to simplify the configuration of a liquid circuit in blood purification devices by automatically opening and closing the pump tubes. This is achieved through a pump tube opening/closing mechanism that utilizes a tube receiving plate, a tube pressing member driving unit, and a plurality of cams. The invention addresses the need for a simple and efficient method of configuring the liquid circuit in blood purification devices. [Extracted from the article]

Nikkiso Company Limited has been issued a patent for a blood purification apparatus. The patent describes a device that allows for blood purification treatment, such as dialysis, by using a blood circuit with flexible tubes. The apparatus includes a blood pump and a dialyzer connected to the arterial and venous blood circuits. The invention aims to accurately calculate the flow rate in the access vessel during blood circulation and includes a measurement mode and a treatment mode. The patent provides a solution to the problem of accurately recognizing and informing medical workers about the state of blood flow rate measurement in the access vessel. [Extracted from the article]

A patent application titled "Blood Purification Device" has been published online by inventors from Japan. The application describes a blood purification device that aims to improve maintainability. The device includes a dialysate supply-and-discharge unit, an extracorporeal circulation unit, and a control unit. The inventors claim that this device offers improved maintainability and provide a detailed description of its components and features. The patent application was filed on May 26, 2022, and made available online on August 1, 2024. [Extracted from the article]

A systematic review and meta-analysis conducted by Zhijie Ling and colleagues in Ganzhou, People's Republic of China, evaluated the therapeutic effect of continuous blood purification (CBP) in children with sepsis. The study included 24 studies and found that CBP reduced levels of inflammatory markers, increased levels of immune markers, improved organ function, and had a lower risk of 28-day mortality in children with sepsis. These findings suggest that CBP may be beneficial for the treatment of sepsis in children. The research has been peer-reviewed and published in the Journal of Infection and Chemotherapy. [Extracted from the article]

Nikkiso Company Limited has been issued a patent for a blood purification device. The device aims to recover plasma or a replenishing liquid remaining in a line and prevent the sending of air bubbles towards the patient after blood purification treatment. The device includes a chamber, a liquid feed line, an air introduction unit, a liquid level adjustment unit, and a control unit. The patent was filed on December 17, 2019, and published online on July 23, 2024. [Extracted from the article]

A patent application by inventors from Nikkiso Co. Ltd. has been made available online for a blood purification apparatus. The apparatus aims to determine if the blood circuit is in the AV coupled state during the drainage process. It includes a blood circuit, a blood pump, a flow channel switch unit, a pressure detection unit, and a control unit. The control unit executes a determination process to monitor the difference in pressure and determine if the blood circuit is closed before executing the drainage process. This invention allows for self-evaluation of the AV coupled state during blood circuit drainage. [Extracted from the article]

A patent application has been submitted by inventors MAEDA, Takuya and TSUJI, Kazuya for a blood purification apparatus. The apparatus is designed to treat renal failure by circulating blood outside the body and filtering out waste products and water. The invention involves introducing air into the blood circuit to help drain residual liquid, reducing the need for a high-output liquid delivery pump. The patent application was filed by Nikkiso Co. Ltd. and provides a detailed description of the apparatus and its components. [Extracted from the article]

A patent application for a blood purification apparatus has been filed by inventors from Shizuoka, Japan. The apparatus is designed to treat renal failure by filtering waste products and water from the blood using a blood purifier. The invention aims to prevent negative pressure in the blood circuit and includes an air introducer to set the dialysate circuit to a positive pressure. The apparatus also includes a controller to control the flow of dialysate and return the purified blood to the body. This patent application provides valuable information for researchers interested in blood purification and dialysis technology. [Extracted from the article]

A patent application has been submitted for a blood purification apparatus and blood purification management system. The invention aims to provide a reliable and simple way to purify the air in a treatment facility during blood purification treatment, such as dialysis. The apparatus includes an air purification unit that works in conjunction with the blood purification unit to purify the air around the patient. The system can be connected to multiple blood purification apparatuses and manages their running schedule. The invention aims to create a clean treatment facility and provide a high-quality treatment environment. [Extracted from the article]

A study conducted at Sichuan University in China explored the efficacy of ulinastatin-assisted continuous blood purification in treating severe sepsis. The study included 240 individuals with severe sepsis, randomly divided into an observation group and a control group. The observation group, which received ulinastatin in addition to continuous blood purification, showed a significantly higher total effective rate of treatment, shorter hospitalization time, and reduced duration of antibiotic treatment compared to the control group. The researchers concluded that ulinastatin can improve clinical symptoms, reduce inflammatory markers, and enhance the overall physiological status of patients with severe sepsis. [Extracted from the article]

A patent has been issued for a blood purification device by the inventors Furuhashi, Tomohiro, Kazinczi, Ferenc, Maki, Hideto, and Ono, Kazuhide. The patent, assigned to Nikkiso Company Limited, describes a device that identifies the tubes used in the blood circuit, liquid supply circuit, and waste liquid circuit of the device. It also detects abnormalities in the tubes based on liquid flow or pressure fluctuations. The device aims to prevent unintended flow rate control and ensure accurate treatment for different patient populations. [Extracted from the article]

A patent application has been submitted for a blood purification apparatus by inventors Tomohiro Suzuki and Syu Tashiro. The apparatus, assigned to Nikkiso Company Limited, is designed to purify a patient's blood by circulating it through a blood circuit and a blood purifier. The apparatus can be switched between a double-needle state and a single-needle state, and includes a chamber member that stores blood during the single-needle state. A connection-checking unit ensures that the chamber member is properly connected to the blood circuit, preventing it from being forgotten. The invention aims to improve the efficiency and safety of blood purification treatment. [Extracted from the article]

A recent study conducted by researchers at Universita Cattolica del Sacro Cuore in Rome, Italy, examined the use of CytoSorb(R) in patients with hepatic dysfunction (HD) after liver transplantation (LT) or extended hepatic resection (EHR). The study aimed to evaluate the safety and effectiveness of CytoSorb(R) in these settings. The results showed a significant reduction in serum total bilirubin levels at the end of treatment, but levels returned to baseline in some patients after discontinuation of therapy. The study concluded that the use of CytoSorb(R) did not show clear benefits in rebalancing clinical and laboratory parameters in patients with HD after LT or EHR. [Extracted from the article]

A patent has been issued for a blood purification apparatus developed by inventors from Nikkiso Company Limited in Tokyo, Japan. The apparatus is designed for dialysis treatment and includes an arterial blood circuit, a venous blood circuit, and a blood purifier. The invention addresses the issue of air introduction into the drain-liquid temporary chamber during the initialization process, which can make it difficult to accurately weigh the drain liquid. The apparatus includes a control unit that executes a draining process to remove the drain liquid and a monitoring process to measure the amount of drain liquid remaining in the chamber. The patent provides variations of the apparatus that include additional features such as a feeding-liquid storage and a weighing device. [Extracted from the article]

A patent has been issued for a blood purification system and solution-preparation-determining apparatus. The system includes a solution-preparing unit, a dialysate-supplying unit, a blood-purification-treatment section, and a determining unit. The determining unit determines whether additional preparation of the undiluted dialysate solution is necessary based on the estimated number of treatment sessions and the actual number of treatment sessions performed. This system aims to accurately determine if additional preparation of the solution is needed in order to avoid shortages during dialysis treatment. The patent is assigned to Nikkiso Company Limited. [Extracted from the article]

A patent has been issued for a blood purification apparatus and method of trapping bubbles therein. The patent describes a blood circuit used in dialysis treatment, which includes an arterial blood circuit and a venous blood circuit connected to a blood purifier. The apparatus includes an air-trap chamber for trapping bubbles in the liquid flowing through the blood circuit. The invention aims to reduce the capacity of the air-trap chamber while still effectively trapping bubbles, thereby improving treatment efficiency. The patent also includes variations of the apparatus and methods for trapping bubbles. The patent was filed by Shingo Ikuma and assigned to Nikkiso Company Limited. [Extracted from the article]

A new report discusses research conducted at Hainan Medical University in Haikou, People's Republic of China, on the impact of continuous blood purification combined with reduced glutathione on endotoxin levels, inflammatory mediators, and the severity of liver injury in septic shock patients. The study included 100 septic shock patients who were randomly divided into study and control groups. Both groups received standard interventions, but the study group also received reduced glutathione therapy. The study found that combining continuous blood purification with reduced glutathione therapy resulted in lower levels of endotoxin and inflammatory mediators, reduced liver injury, and improved patient recovery. The researchers suggest that future studies should validate these findings in a larger and more diverse population of septic shock patients. [Extracted from the article]

Nikkiso Company Limited, based in Tokyo, Japan, has been issued a patent for a blood purification apparatus. The patent, filed on September 30, 2021, and published online on April 2, 2024, describes a technique for administering a liquid drug to a patient during a blood purification treatment. The apparatus includes a blood circuit, a blood purification unit, a blood pump, a substitution line, and an infusion portion. The control unit of the apparatus executes a drug introduction mode, allowing the liquid drug to be introduced into the blood circuit along with the substitution fluid. The invention aims to prevent blood from flowing into the substitution line and to provide medical workers with an appropriate timing of liquid drug infusion. [Extracted from the article]

Nikkiso Company Limited has been issued a patent for a blood purification system. The system includes a blood purification apparatus that provides treatment to patients, a managing apparatus that stores information on the treatment in a time course, and a display unit that shows the information. The system also includes an extracting unit that searches and extracts reference histories, a list-creating unit that creates a list of the reference histories, and a display control unit that controls the display of the list. The system aims to effectively utilize accumulated histories and help medical workers take quick and appropriate actions during treatment. [Extracted from the article]

A patent has been issued for a blood purification apparatus developed by inventors Ishizaki and Matsuo and assigned to Nikkiso Company Limited. The apparatus is designed to perform blood purification treatment, such as dialysis, by circulating the patient's blood outside the body and purifying it using a dialyzer. The invention aims to prevent waste liquid from flowing through the ultrafiltration pump during the process, which can lead to the accumulation of waste products and affect the accuracy of ultrafiltration. The apparatus includes a blood circuit, a blood purification device, a dialysate introduction line, a dialysate drain line, a liquid-delivering device, and an ultrafiltration pump. The ultrafiltration pump is connected to an ultrafiltration line, which allows the pump to draw dialysate from the dialysate introduction line and perform ultrafiltration. The control device ensures that the volume of dialysate introduced into the blood purification device is smaller than the volume of waste liquid drained from it. The apparatus also includes a synchronization device to coordinate the actions of the liquid-delivering device and the ultrafiltration pump. The patent provides various claims and further details about the apparatus. [Extracted from the article]

Researchers from the University Medical Center Hamburg-Eppendorf have published a new study on the role of extracorporeal blood purification techniques in managing septic hyperinflammation, a critical aspect of sepsis. The study evaluates the effectiveness of various blood purification methods in removing cytokines and endotoxin and improving hemodynamic stability. However, the current evidence does not strongly support these techniques in significantly improving survival rates in septic patients, highlighting the need for further research. The study provides an overview of sepsis, focusing on the dynamics of immune response and the involvement of neutrophils and the endothelium in the disease's progression. [Extracted from the article]

A study conducted at the First Affiliated Hospital of Hainan Medical College in China evaluated the effectiveness of personalized dietary interventions in improving the nutritional status and overall health of patients undergoing dialysis. The study found that patients who received individualized dietary counseling showed significant improvements in albumin, hemoglobin, potassium, and phosphorus levels after six months. They also had a higher rate of adherence to dietary recommendations and reported enhancements in energy and protein consumption, as well as improvements in physical, emotional, social, and overall health perception scores. The findings suggest that personalized dietary interventions can greatly improve the nutritional status, biochemical profile, and quality of life of patients undergoing dialysis. [Extracted from the article]

A patent has been issued for a blood purification device developed by Nikkiso Co. Ltd. The device aims to simplify the handling of blood purification devices by including a removable cassette that houses a container for removed water. The device body includes a load detector that measures the load of the removed water container, and a load transmission mechanism transmits this load to the load detector. The cassette also includes components such as a dialyzer and a dialysate regeneration column. The invention seeks to improve the efficiency and convenience of blood purification procedures. [Extracted from the article]

A recent study conducted at Xiangya Hospital in Hunan, China, investigated the effects of blood purification membranes modified with a platelet phosphodiesterase (PDE) inhibitor on platelet adhesion, activation, aggregation, and secretion. The researchers found that the modified membranes effectively inhibited platelet adhesion and activation, as well as reduced platelet aggregation and secretion levels. The membranes also demonstrated good anticoagulant properties and biocompatibility in mouse experiments. The study suggests that these modified membranes could be used in blood purification for critically ill patients. [Extracted from the article]

A patent has been issued for a blood purification apparatus developed by Nikkiso Company Limited. The apparatus is designed to purify a patient's blood through a blood circuit that includes an arterial blood circuit and a venous blood circuit. It utilizes a dialysate temporary chamber and a substitution-fluid temporary chamber to store and introduce dialysate and substitution fluid into the blood purifier. The apparatus also includes pumps and a control unit to regulate the flow of these fluids. The invention aims to improve the layout and efficiency of the blood purification process. [Extracted from the article]

A recent study conducted by the Fraunhofer Institute for Cell Therapy and Immunology IZI in Rostock, Germany, explored the use of miniaturized adsorbers in the treatment of multiple sclerosis (MS). The researchers used these devices to mimic the immunoadsorption (IA) treatment of MS patients in vitro. The study found that the IA treatment resulted in reduced levels of cytokines and chemokines in the plasma, as well as a decrease in the migration of neutrophils and improved integrity of the endothelial cell barrier. These findings suggest that IA may reduce the infiltration of cells into the central nervous system and prevent blood-brain barrier breakdown. The study highlights the potential of using miniaturized adsorbers to investigate the mechanisms of action of blood purification therapies in various diseases. [Extracted from the article]

A recent study on sepsis highlights the challenges faced by clinicians in diagnosing and treating this condition, which is associated with high mortality rates. The study emphasizes the importance of specific sepsis care programs in hospitals and the need for hemodynamic resuscitation, antibiotic treatment, life support, and focus control. It also discusses the significance of perfusion and hemodynamic coherence in determining the ideal time for vasopressor treatment and appropriate fluid therapy dosage. Additionally, the study explores the potential benefits of blood purification therapies in managing septic shock. [Extracted from the article]

Researchers at Hebei Medical University in Shijiazhuang, China have conducted a study on the relationship between oxidative phosphorylation and NDUFB11 and venous thromboembolism (VTE). They analyzed gene expression data and found that NDUFB11 is highly expressed in catheter-related VTE during continuous blood purification, potentially leading to the formation of venous thrombosis through the oxidative phosphorylation pathway. The study provides insights into the molecular mechanisms underlying VTE and may contribute to the development of new therapeutic strategies. [Extracted from the article]

A recent survey conducted by researchers at Hannover Medical School examined the use of extracorporeal blood purification (EBP) as a treatment for sepsis and septic shock. The survey found that 74.5% of participants use EBP in their clinical practice, with unselective cytokine adsorption and therapeutic plasma exchange being the most commonly used modalities. However, while there is a theoretical rationale for the use of EBP, the clinical evidence supporting its effectiveness is limited. The survey suggests that therapeutic plasma exchange may have the highest potential for further exploration in clinical trials. [Extracted from the article]

Nikkiso Co. Ltd, a company based in Tokyo, Japan, has been issued a patent for a tube connector, extracorporeal circulation circuit, and blood purification device. The patent addresses the problem of bubbles forming in the tube connector during the priming process of hemodialysis, which can hinder automation and workability. The invention aims to provide a compact tube connector that suppresses the retention of bubbles. The patent includes detailed claims and descriptions of the tube connector, extracorporeal circulation circuit, and blood purification device. [Extracted from the article]

A study conducted at Tianjin Medical University General Hospital in China examined the impact of targeted nursing combined with nutritional intervention on pyemia patients undergoing blood purification therapy. The study divided patients into a control group and an experimental group, with the experimental group receiving targeted nursing and nutritional interventions. The results showed that the experimental group had lower levels of serum calcium and phosphorus, and higher levels of serum albumin, prealbumin, total plasma protein, transferrin, and fibronectin compared to the control group. The experimental group also had a lower incidence of complications and higher quality of life scores. The study suggests that targeted nursing combined with nutritional intervention can effectively improve the nutritional status, reduce complications, and enhance the quality of life for pyemia patients undergoing blood purification therapy. [Extracted from the article]